HR 7736, the RELIEF Act, requires U.S. Customs and Border Protection to refund tariffs collected under the International Emergency Economic Powers Act (IEEPA) on imports entered on or after January 1, 2025. It directly affects importers of record by mandating automatic refunds within 90 days of the bill's enactment, without requiring them to submit applications or protests. The bill directs Customs to use existing data to calculate and disburse refunds for all affected tariff collections, including entries involving goods withdrawn from warehouse for consumption. This policy change eliminates the need for importers to seek refunds through separate processes, streamlining the recovery of overpaid duties.
HR 7742, the Keep It Moving Act, sets strict deadlines for the Federal Communications Commission (FCC) to review and approve applications for telecom license transfers or spectrum lease control changes. It requires the FCC to make a completeness determination within 15 days, issue a final approval decision within 180 days (or 1 year for complex cases), and automatically deem applications complete if deadlines are missed. If the FCC fails to meet these timelines, applicants can seek a court order forcing approval or a hearing to justify denial. The bill excludes minor "pro forma" transactions (like routine transfers) that don’t require prior FCC approval.
HR 7740, the African American History Act of 2026, authorizes $4 million annually for the National Museum of African American History and Culture to develop educational resources and support teaching about African American history. The bill directs the museum to create digital and print materials, provide teacher training, and expand access to curriculum resources for K-12 and college classrooms. It requires annual reports to Congress on fund usage and expires in 2030. This program directly affects educators and students by enhancing classroom materials and professional development on African American history.
This bill requires the Bureau of Prisons to employ at least one full-time, board-certified OB-GYN at every federal prison housing female inmates. It mandates specific services including menstrual care, contraception, prenatal care, cancer screenings, and postpartum support, along with patient protections like informed consent and the right to refuse non-emergency care. The bill also requires initial OB-GYN visits within 14 days of incarceration and establishes a process for referrals to other specialists without delays. Annual reports to Congress will track facility compliance, staffing vacancies, and health outcomes like prenatal visits, childbirths, and pregnancy-related deaths.
HRES 1082 is a symbolic resolution recognizing 250 years of Polish-American friendship and affirming U.S. support for Poland’s democracy, sovereignty, prosperity, and security. It specifically calls for continued U.S. military stationing in Poland to support defense coordination and training with Polish forces, and expresses gratitude for Poland’s historical and ongoing partnership, including recent support for Ukraine. The resolution highlights key milestones like Poland’s NATO membership, defense investments, and refugee assistance for Ukrainians. As a non-binding resolution, it does not change laws but formally strengthens diplomatic recognition of the alliance.
HRES 1084 designates February 28 as "HIV is Not a Crime Awareness Day" to address the criminalization of people living with HIV. The resolution calls for ending state laws that impose harsh penalties or criminalize consensual acts based solely on HIV status - regardless of transmission risk, intent, or disclosure - and notes these laws disproportionately impact Black and brown communities, Black women, and transgender women. It urges education for law enforcement and communities, removal of outdated HIV criminalization laws, and increased support for HIV prevention, testing, treatment, and care programs. The resolution does not create new laws but advocates for policy changes to align with current medical understanding and reduce stigma.
HRES 1079 is a non-binding House resolution recognizing Charcot-Marie-Tooth disease (CMT) as a significant health condition affecting approximately 126,000 people in the U.S. and millions globally. It expresses the House’s support for increased federal funding for CMT research at the National Institute of Neurological Disorders and Stroke (NINDS) within the National Institutes of Health (NIH). The resolution specifically highlights that CMT research funding decreased in 2022 compared to 2021 and emphasizes the need for sustained investment in studying this inherited nerve disorder, which currently has no cure. As a recognition resolution, it does not allocate funds but formally urges continued NIH support for CMT and rare disease research.
HRES 1080 is a symbolic resolution recognizing and celebrating Black History Month 2026, focusing on its theme "A Century of Black History Commemorations." It highlights historical figures and events central to Black history, including Carter G. Woodson’s founding of Negro History Week (the precursor to Black History Month), Juneteenth, and key moments like the 1865 Charleston commemoration. The resolution emphasizes how Black history commemorations counter historical erasure and affirm Black contributions to U.S. history, referencing figures like Mary McLeod Bethune and W.E.B. Du Bois. As a ceremonial resolution, it has no binding effect but aims to raise awareness of Black achievements through official recognition.
S 3914 establishes two new offices within the Supreme Court: an Office of Ethics Counsel to advise justices and their spouses on ethics matters (like financial disclosures, gifts, and conflicts of interest), and an Office of Investigative Counsel to review formal ethics complaints filed by top congressional leaders. The Ethics Counsel provides mandatory biannual training to justices and submits annual reports to Congress on ethics advice given. The Investigative Counsel handles complaints, conducts investigations within 60 days of filing, and submits findings to the Chief Justice (or senior associate justice if the Chief is the subject), with reports also shared with relevant congressional committees. This bill directly affects Supreme Court justices, their spouses, and dependents by creating formal processes for ethics guidance and oversight.
The Government Surveillance Transparency Act of 2026 requires federal, state, and tribal courts to publicly disclose criminal surveillance orders, applications, and inventories after a maximum 180-day sealing period, with strict requirements for extensions. The bill mandates courts to publish detailed public reports about surveillance requests, including the nature of investigations and the agencies involved, and requires electronic filing of all surveillance documents. It creates a unique case numbering system for surveillance orders and requires automatic unsealing of documents after the sealing period expires. The law applies to all courts conducting surveillance, with implementation phased to allow time for system upgrades, and aims to increase transparency around government surveillance activities while balancing legitimate law enforcement needs.
This bill, known as Gwenn's Law, directs the National Institutes of Health to launch public awareness campaigns aimed at increasing women's participation in clinical trials, with a specific focus on research for rare diseases. It authorizes $10 million annually from 2027 to 2031 to fund these outreach efforts at hospitals, clinics, and other healthcare locations. The legislation also establishes a permanent interagency task force within HHS to coordinate rare disease research and requires the department to submit a public action plan within 180 days outlining how to improve treatment options for rare conditions that disproportionately affect women.
HR 7693, "Leo’s Law," extends existing exclusivity protections for certain orphan drugs by 180 days to address pandemic-related delays. It applies to drugs designated for rare diseases that had applications submitted during the COVID-19 emergency period (Dec 2019-March 2023), were approved under specific pathways, and have no non-rare disease indications. Key provisions extend periods like the 12-year market exclusivity under the Public Health Service Act and 5-year protections under the Federal Food, Drug, and Cosmetic Act. The bill does not create new incentives but temporarily lengthens existing protections for drug developers already navigating pandemic disruptions. This change applies only to qualifying orphan drugs meeting all specified criteria during the defined emergency period.
